EP
AVDL

Essential Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Essential Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11
Closed -$237 – 2857
2025
Q4 		$237 Hold
11
– – ﹤0.01% 2399
2025
Q3 		$168 Buy
+11
New +$143 ﹤0.01% 2422

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Essential Partners's AVDL Position: Q1 2026 in Review

Essential Partners sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 11 shares — an estimated $237 sold.

Essential Partners first reported a position in AVDL in Q3 2025 and held it in 2 quarters. The position peaked at $237 in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Essential Partners reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Essential Partners sold 11 Avadel Pharmaceuticals shares in Q1 2026, an estimated $237.
  • Essential Partners first reported a position in Avadel Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Essential Partners's Avadel Pharmaceuticals position peaked at $237 in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Essential Partners's 13F filing for Q1 2026, filed 21 May 2026.